virtual
experiment
highthroughput
screen
ht
wide
use
identifi
novel
ligand
drug
develop
despit
success
method
haunt
fals
posit
compound
initi
appear
desir
biolog
activ
closer
evalu
found
act
spuriou
mechan
often
counterfeit
screen
hit
peculiar
behavior
reconcil
canon
mode
inhibit
compound
ultim
found
development
deadend
discard
typic
great
deal
time
resourc
devot
frustrat
caus
molecul
compound
preval
estim
given
experiment
ht
ratio
fals
posit
true
posit
best
like
enrich
phoni
inhibitor
led
increas
scrutini
hit
list
increas
interest
develop
filter
counterscreen
rapidli
recogn
elimin
nonleadlik
compound
consider
toward
end
work
last
decad
devot
understand
origin
falseposit
screen
hit
experiment
artifact
compound
impur
assay
interfer
wellknown
caus
inhibitor
promiscu
due
reactiv
group
privileg
scaffold
also
describ
recent
aggreg
format
emerg
potenti
mechan
promiscu
inhibit
model
propos
nonspecif
inhibitor
form
aggreg
solut
aggreg
speci
respons
enzym
inhibit
figur
preliminari
studi
suggest
aggregateform
promiscu
compound
may
common
among
screen
librari
hit
list
chapter
initi
focu
nonspecif
enzym
inhibit
caus
aggregateform
molecul
review
experiment
method
identif
compound
comput
algorithm
predict
type
promiscu
inhibitor
discuss
outstand
question
regard
promiscu
inhibitor
drug
discoveri
consid
late
experiment
virtual
ht
commonli
use
identifi
new
lead
drug
design
although
variou
screen
techniqu
algorithm
develop
becam
appar
output
largescal
method
suboptim
hit
list
popul
domin
nonspecif
compound
peculiar
properti
steep
inhibit
curv
flat
structureact
relationship
sar
complex
timedepend
behavior
despit
use
filter
reactiv
chemic
swill
druglik
problemat
molecul
continu
appear
screen
hit
list
compound
caus
much
frustrat
often
abandon
signific
effort
invest
explor
underli
mechan
respons
perplex
behavior
compound
initi
investig
includ
screen
hit
lead
use
experiment
tool
clinic
prescrib
drug
compound
studi
found
inhibit
divers
model
enzym
includ
blactamas
chymotrypsin
dihydrofol
reductas
bgalactosidas
promiscu
compound
show
timedepend
inhibit
sensit
enzym
concentr
presenc
bovin
serum
albumin
bsa
ionic
strength
base
observ
hypothes
nonspecif
compound
form
aggreg
solut
aggreg
particl
caus
enzym
inhibit
figur
consist
hypothesi
dynam
light
scatter
dl
transmiss
electron
microscopi
reveal
promiscu
compound
form
particl
order
nm
diamet
particl
absent
solut
nonpromiscu
compound
aggreg
particl
interact
enzym
molecul
caus
inhibit
centrifug
experi
suggest
direct
interact
aggregateform
inhibitor
enzym
molecul
interact
disrupt
addit
deterg
triton
aggreg
format
enzym
inhibit
promiscu
compound
also
prevent
rapidli
revers
addit
triton
addit
microscopi
studi
show
protein
molecul
adsorb
onto
surfac
aggreg
particl
although
absorpt
aggreg
interior
could
exclud
interact
also
prevent
addit
deterg
triton
account
observ
propos
promiscu
compound
form
aggreg
solut
enzym
molecul
adsorb
onto
surfac
aggreg
particl
result
revers
enzym
inhibit
figur
sinc
first
propos
model
grow
number
research
group
identifi
potenti
aggregatebas
inhibitor
among
screen
hit
tabl
observ
addit
initi
smallscal
evalu
preval
aggreg
suggest
occur
among
screen
hit
smallmolecul
reagent
use
lab
surprisingli
even
clinic
use
drug
recent
studi
evalu
random
druglik
molecul
suggest
show
experiment
signatur
aggregatebas
promiscu
potenti
widespread
occurr
aggreg
former
much
interest
develop
rapid
experiment
method
identif
promiscu
compound
also
grow
interest
develop
comput
model
predict
compound
like
act
aggreg
former
filter
could
use
remov
suspect
molecul
screen
librari
hit
list
experiment
comput
effort
consid
turn
follow
section
peculiar
experiment
signatur
aggregateform
compound
use
distinguish
specif
wellbehav
inhibitor
sever
research
group
use
characterist
triag
screen
hit
potenti
promiscu
appropri
experi
rang
complex
intens
rapid
biochem
assay
much
labori
microscopi
studi
depend
purpos
research
effort
experi
tailor
appropri
earlystag
discoveri
program
follow
experi
perform
answer
question
hit
like
inhibit
screen
target
aggreg
answer
ye
unlik
hit
favor
start
point
lead
design
drop
consider
immedi
pain
throw
compound
earli
process
pale
comparison
agoni
abandon
lead
sever
nonproduct
develop
cycl
answer
question
one
element
hit
potenti
reassuringli
establish
necessari
experi
exampl
recent
applic
drug
discoveri
project
describ
detail
recip
perform
assay
describ
elsewher
biochem
assay
promiscu
fortun
screen
program
face
evalu
ten
thousand
hit
inform
experi
among
easiest
perform
amen
highthroughput
method
often
experiment
assay
initi
identifi
screen
hit
easili
modifi
accomplish
mani
initi
test
promiscu
addit
protocol
use
assay
mechan
promiscu
chemic
reactiv
origin
assay
lack
suffici
dynam
rang
otherwis
difficult
alter
may
simpler
use
easili
purchas
model
enzym
system
chymotrypsin
blactamas
colorimetr
kinet
assay
proven
especi
robust
purpos
particular
compon
assay
affect
outcom
instanc
ionic
strength
ph
buffer
alter
aggreg
inhibit
properti
compound
mm
potassium
phosphat
ph
previous
found
use
increas
enzym
concentr
presenc
excess
protein
albumin
decreas
appar
inhibit
aggreg
start
enzym
concentr
nm
typic
ideal
solut
inhibitor
substrat
prepar
fresh
buffer
dimethyl
sulfoxid
dmso
stock
dilut
buffer
final
dmso
concentr
assay
low
possibl
prefer
less
substrat
concentr
typic
greater
k
reaction
allow
maxim
veloc
presenc
deterg
triton
inhibit
aggregateform
inhibitor
markedli
attenu
instanc
inhibit
blactamas
mm
solut
tetraiodophenolphthalein
prototyp
aggreg
decreas
absenc
deterg
presenc
triton
inde
triton
rapidli
revers
inhibit
blactamas
without
affect
specif
wellbehav
inhibitor
enzym
figur
date
deterg
sensit
easiest
way
discrimin
aggreg
nonaggreg
therefor
rapid
method
identifi
aggregatebas
inhibitor
repeat
screen
assay
addit
triton
typic
protocol
consist
incub
fresh
deterg
inhibitor
ic
concentr
inhibitor
reduc
enzym
activ
enzym
min
initi
reaction
substrat
inhibit
due
aggreg
inhibit
decreas
less
presenc
deterg
may
also
use
consid
ad
triton
baselin
assay
buffer
prophylact
measur
prevent
aggregateform
compound
appear
inhibitor
first
control
experi
requir
establish
addit
triton
significantli
affect
reaction
rate
assay
compon
neg
control
experi
show
wellbehav
inhibitor
system
affect
deterg
posit
control
show
known
aggreg
attenu
deterg
worth
note
discuss
chapter
emphas
use
triton
shown
revers
enzym
inhibit
aggreg
figur
deterg
employ
agent
studi
promiscu
saponin
chap
rel
simplic
deterg
sensit
use
grow
number
drug
discoveri
project
triag
compound
promiscu
tabl
instanc
use
librari
compound
deriv
phosphatas
inhibitor
dysidiolid
koch
cowork
found
select
inhibitor
three
enzym
structur
similar
librari
compound
assay
target
enzym
presenc
absenc
triton
ultim
identifi
specif
inhibitor
deterg
also
use
studi
inhibit
ertiprotafib
compound
reach
phase
ii
clinic
trial
tabl
ic
ertiprotafib
nm
increas
addit
triton
observ
combin
properti
compound
consist
aggregatebas
mechan
inhibit
key
observ
lead
develop
aggreg
hypothesi
promiscu
inhibitor
sensit
concentr
enzym
instanc
increas
concentr
blactamas
nm
suffici
increas
ic
aggregateform
compound
even
inhibitor
present
micromolar
concentr
abil
nanomolar
enzym
titrat
micromolar
inhibitor
suggest
activ
form
inhibitor
might
aggreg
mani
individu
inhibitor
molecul
although
ratio
individu
inhibitor
molecul
enzym
molecul
might
greater
ratio
aggreg
particl
enzym
molecul
would
much
lower
evalu
screen
hit
properti
concentr
target
enzym
increas
assay
repeat
inhibitor
ic
obtain
baselin
enzym
concentr
aggreg
format
involv
inhibit
ought
decreas
less
greater
concentr
enzym
assay
requir
ratio
inhibitor
enzym
remain
elev
order
greater
even
enzym
concentr
increas
mani
assay
may
abl
toler
increas
enzym
concentr
due
cost
limit
reagent
avail
increas
reaction
rate
make
technic
difficult
obtain
accur
veloc
measur
case
may
help
decreas
initi
assay
concentr
enzym
use
altern
substrat
slower
reaction
rate
deterg
assay
describ
wellbehav
inhibitor
affect
increas
enzym
concentr
serv
neg
control
known
aggreg
shown
sensit
enzym
concentr
use
posit
control
protocol
also
use
sever
research
group
evalu
screen
hit
exampl
dispers
blue
mg
ml
phosphomannomutasephosphoglucomutas
pmmpgm
ic
mm
enzym
concentr
increas
mg
ml
compound
show
detect
inhibit
mm
similarli
ic
ertiprotafib
increas
mm
concentr
enzym
increas
nm
inclus
bsa
also
decreas
potenc
aggregatebas
inhibitor
similar
mechan
increas
enzym
concentr
except
enzym
molecul
displac
inhibitor
particl
inert
protein
instead
activ
enzym
consequ
addit
bsa
screen
assay
use
accomplish
equival
purpos
exampl
see
tabl
one
earliest
warn
sign
lead
discoveri
aggreg
abil
inhibit
dissimilar
target
exampl
rottlerin
wide
use
kinas
inhibitor
ic
mm
pkcd
mm
blactamas
mm
chymotrypsin
mm
malat
dehydrogenas
sinc
becom
clear
aggreg
inhibit
varieti
enzym
rang
blactamas
kda
monom
bgalactosidas
kda
tetram
ideal
screen
hit
consider
least
one
counterscreen
perform
enzym
unrel
target
enzym
term
structur
function
ligand
recognit
depend
level
certainti
requir
test
one
dissimilar
enzym
may
suffici
test
two
provid
addit
reassur
screen
across
receptor
also
allow
investig
mechan
promiscu
chemic
reactiv
privileg
scaffold
nonspecif
inhibit
mechan
may
suffici
drop
compound
optim
studi
secondari
screen
practic
experiment
robust
system
readili
avail
compon
straightforward
assay
readout
use
betalactamas
chymoptrypsin
malat
dehydrogenas
use
success
past
may
conveni
use
enzym
alreadi
known
research
group
instanc
fattorusso
colleagu
assay
novel
caspas
inhibitor
discov
combin
nmr
comput
screen
project
metalloproteas
also
investig
laboratori
control
experi
assay
straightforward
specif
inhibitor
target
enzym
enzym
use
counterscreen
crossreact
posit
control
experi
known
aggreg
shown
inhibit
enzym
studi
practic
hit
often
test
relat
enzym
evalu
specif
within
protein
class
across
speci
instanc
blanchard
cowork
use
ht
compound
identifi
novel
coronaviru
proteinas
inhibitor
seri
filter
hit
yield
five
compound
ic
valu
mm
target
two
compound
inhibit
coronaviru
proteas
four
proteas
baldwin
colleagu
screen
compound
librari
find
novel
inhibitor
dihydroorot
dehydrogenas
plasmodium
falciparum
followup
screen
identifi
competit
inhibitor
ic
nm
parasit
enzym
mm
human
isozym
approach
extend
recent
technolog
develop
allow
test
compound
multipl
enzym
parallel
instanc
proteomicsbas
method
enzym
microarray
describ
techniqu
provid
evalu
inhibitor
specif
sever
enzym
simultan
futur
develop
along
line
expect
preincub
aggregatebas
inhibitor
enzym
increas
appar
ic
compound
sever
mechan
could
account
observ
slow
onrat
coval
bind
explor
origin
timedepend
behavior
aggreg
tipton
group
conduct
thorough
analysi
kinet
behavior
dispers
blue
result
suggest
slowbind
occur
compound
interact
target
enzym
pmmpgm
instead
found
compound
behav
parabol
noncompetit
inhibitor
propos
kinet
signatur
timedepend
inhibit
nonlinear
depend
inhibitor
concentr
may
marker
aggreg
futur
studi
evalu
gener
observ
certainli
anticip
meantim
note
timedepend
inhibit
consist
sever
mode
enzym
inhibit
singularli
suffici
denot
compound
aggreg
typic
test
time
depend
ic
determin
incub
enzym
inhibitor
min
initi
reaction
substrat
assay
repeat
except
substrat
first
mix
inhibitor
ic
concentr
reaction
initi
addit
enzym
inhibit
without
incub
decreas
less
result
consist
timedepend
behavior
observ
aggreg
control
experi
includ
repeat
assay
specif
nontimedepend
inhibitor
target
enzym
well
known
aggreg
protocol
usual
perform
conjunct
assay
evalu
inhibitor
behavior
eg
see
observ
steep
inhibit
curv
often
associ
undesir
screen
hit
experiment
properti
use
filter
triag
compound
exampl
search
coronaviru
inhibitor
blanchard
cowork
elimin
compound
sigmoid
semilogarithm
doserespons
curv
aggregateform
inhibitor
also
shown
steep
inhibit
curv
rel
classic
behav
inhibitor
although
mechanist
understand
experiment
observ
await
studi
light
scatter
biochem
experi
describ
provid
phenomenolog
support
identif
aggregatebas
inhibitor
yield
direct
evid
presenc
aggreg
particl
obtain
data
biophys
method
dl
necessari
dl
grow
number
applic
biolog
materi
scienc
discuss
focu
use
dl
determin
particl
present
solut
promiscu
inhibitor
size
conjunct
assay
previous
describ
dl
complet
seri
experi
typic
need
character
promiscu
aggregatebas
inhibitor
dl
commonli
use
analyz
particl
diamet
nm
standard
setup
sampl
solut
studi
place
chamber
expos
laser
particl
sampl
caus
laser
light
scatter
detector
fix
angl
rel
chamber
record
scatter
photon
period
time
usual
ten
second
minut
particl
sampl
undergo
brownian
motion
intens
scatter
light
measur
detector
fluctuat
typic
microsecond
timescal
fluctuat
reflect
rate
diffus
particl
solut
turn
depend
hydrodynam
radiu
particl
accord
stokeseinstein
equat
necessari
calcul
perform
softwar
provid
dl
instrument
given
certain
assumpt
particl
shape
distribut
hydrodynam
radiu
use
measur
particl
size
brief
explan
method
detail
theori
practic
dl
see
descript
santo
wyatt
analysi
promiscu
inhibitor
first
task
determin
particl
present
graphic
determin
shape
autocorrel
function
obtain
dl
experi
instanc
rottlerin
known
promiscu
aggregateform
inhibitor
yield
autocorrel
function
welldefin
decay
microsecond
timescal
shown
figur
true
anoth
promiscu
kinas
inhibitor
figur
surprisingli
suramin
compound
known
inhibit
multipl
target
produc
autocorrel
function
poorli
defin
decay
suggest
form
aggreg
solut
figur
addit
use
note
averag
intens
scatter
light
detector
experi
usual
report
count
per
second
cp
kilocount
per
second
kp
absolut
valu
intens
depend
particular
instrument
use
solut
known
particl
free
filter
water
yield
averag
intens
least
order
magnitud
less
solut
known
contain
particl
latex
bead
albumin
therefor
worthwhil
conduct
posit
neg
control
experi
evalu
signaltonois
ratio
instrument
particl
present
next
step
determin
size
typic
calcul
softwar
accompani
instrument
result
differ
algorithm
even
softwar
packag
vari
markedli
base
assumpt
particl
shape
worthwhil
test
system
use
particl
known
size
latex
bead
standard
albumin
recent
develop
dl
technolog
allow
coupl
dl
highperform
liquid
chromatographi
hplc
column
provid
rapid
eluent
analysi
particular
interest
screen
purpos
least
two
compani
wyatt
technolog
corpor
precis
detector
inc
develop
highthroughput
dl
increas
number
compound
studi
method
grow
number
research
group
incorpor
dl
evalu
hit
lead
compound
instanc
klebe
group
use
dl
rule
aggreg
contributor
inhibit
trnaguanin
transglycosylas
sever
hit
identifi
flexxbas
screen
similarli
wang
cowork
use
light
scatter
rule
aggreg
contributor
activ
novel
nonnucleosid
revers
transcriptas
inhibitor
nnrti
techniqu
also
use
confirm
presenc
particl
solut
suspect
promiscu
inhibitor
soelaiman
colleagu
use
dock
identifi
new
inhibitor
edema
factor
toxin
secret
bacillu
anthraci
three
activ
compound
evalu
dl
one
found
form
particl
greater
nm
diamet
tipton
group
also
use
dl
analysi
dispers
blue
mm
promiscu
ligand
compound
observ
form
particl
mean
radiu
nm
averag
scatter
intens
kcp
dl
also
use
explor
factor
influenc
aggreg
small
molecul
report
arnold
group
diaryltriazin
diarylpyrimidin
nnrti
studi
dl
evalu
effect
ph
compound
concentr
aggreg
size
compound
found
form
particl
solut
three
compound
studi
detail
aggreg
size
increas
ph
increas
aggreg
size
also
found
increas
inhibitor
concentr
increas
mm
intriguingli
compound
particl
radii
nm
favor
absorpt
compound
radii
greater
nm
propos
system
adsorpt
drug
depend
format
appropri
size
aggreg
confoc
fluoresc
transmiss
electron
microscopi
use
visual
small
molecul
aggreg
explor
interact
particl
protein
lowresolut
imag
obtain
confoc
studi
green
fluoresc
protein
gfp
presenc
aggreg
initi
imag
obtain
method
suggest
inhibitor
aggreg
caus
gfp
accumul
cluster
cluster
dissolv
upon
addit
triton
figur
notabl
gfp
retain
fluoresc
signal
presenc
suggest
protein
denatur
aggreg
figur
higher
resolut
imag
similar
solut
bgalactosidas
obtain
transmiss
electron
microscopi
show
protein
adsorb
onto
surfac
inhibitor
aggreg
figur
addit
deterg
interact
prevent
figur
observ
combin
biochem
biophys
studi
suggest
enzym
adsorb
onto
surfac
aggreg
particl
therebi
inhibit
although
absorpt
aggreg
interior
exclud
furthermor
interact
aggreg
enzym
prevent
revers
addit
triton
electron
microscopi
intens
process
typic
amen
screen
although
least
one
report
research
program
use
transmiss
electron
microscopi
evalu
novel
drug
lead
aggreg
techniqu
also
use
visual
aggreg
form
nnrti
studi
arnold
group
although
compound
consid
promiscu
aggreg
format
suggest
mediat
bioavail
drug
addit
confirm
assay
beyond
experi
describ
sever
test
one
could
consid
perform
evalu
screen
hit
peculiar
behavior
simpli
origin
assay
could
repeat
exactli
condit
evalu
trivial
experiment
error
rigor
propos
compound
librari
screen
target
three
differ
assay
protocol
agreement
assay
consequ
may
use
design
altern
assay
protocol
target
rescreen
entir
librari
less
labori
initi
hit
altern
format
depend
particular
screen
protocol
use
may
inform
test
compound
set
interfer
assay
readout
instanc
jenkin
colleagu
use
fluorescencebas
ht
identifi
angiogenin
inhibitor
initi
set
hit
replat
activ
fluoresc
substrat
evalu
hit
interfer
fluoresc
readout
strikingli
hit
found
interfer
screen
chemic
reactiv
may
also
product
abil
screen
hit
inhibit
divers
receptor
describ
may
first
sign
reactiv
timedepend
behavior
may
also
suggest
irrevers
reaction
directli
author
found
use
repeat
screen
assay
presenc
dithiothreitol
dtt
evalu
hit
thiol
reactiv
altern
mass
spectrometri
ms
use
evalu
compound
adduct
format
less
glamor
less
importantli
often
use
evalu
puriti
screen
hit
observ
activ
may
due
contamin
varieti
approach
possibl
simpli
new
solut
compound
prepar
fresh
powder
powder
differ
lot
altern
compound
repurifi
reassay
rigor
analysi
hplc
ms
employ
detect
impur
given
expens
experiment
work
desir
minim
effort
spent
fals
posit
consider
interest
develop
comput
method
predict
compound
like
behav
promiscu
sinc
lipinski
semin
work
show
drug
share
common
set
easili
identifi
properti
much
effort
devot
predict
druglik
behavior
base
chemic
structur
follow
section
review
recent
comput
approach
identifi
variou
class
promiscu
compound
defin
roch
group
frequent
hitter
compound
appear
activ
multipl
screen
project
across
rang
target
includ
reactiv
speci
compound
interfer
assay
privileg
scaffold
predict
compound
like
act
frequent
hitter
roch
colleagu
first
develop
databas
known
frequent
hitter
compound
cull
compound
hit
least
eight
differ
ht
assay
compound
inhous
depositori
request
least
six
differ
discoveri
project
addit
compound
variou
site
within
roch
eleven
team
medicin
chemist
vote
structur
identifi
molecul
accord
expert
opinion
experi
like
frequent
hitter
obtain
set
nonfrequ
hitter
divers
set
compound
roch
human
drug
databas
select
final
data
set
contain
frequent
hitter
nonfrequ
hitter
structur
analysi
leadscop
reveal
singl
substructur
suffici
identifi
frequent
hitter
extend
analysi
ghose
crippen
descriptor
calcul
compound
data
set
use
defin
partial
least
squar
pl
multivari
linear
regress
model
pl
model
correctli
predict
frequent
hitter
nonfrequ
hitter
group
develop
nonlinear
model
use
neural
network
base
ghose
crippen
descriptor
final
model
correctli
classifi
frequent
hitter
nonfrequ
hitter
author
explain
frequent
hitter
synonym
undesir
structur
instanc
ligand
bind
similar
set
receptor
crossreact
common
substructur
therefor
model
intend
elimin
compound
priorit
compound
purchas
librari
design
test
subsequ
effort
identifi
frequent
hitter
describ
merkwirth
cowork
variou
singl
ensembl
method
includ
knearest
neighbor
classifi
support
vector
machin
svm
singl
ridg
regress
model
deriv
binari
classif
compound
model
train
frequent
hitter
data
set
describ
best
model
crossvalid
correl
coeffici
misclassif
rate
improv
misclassif
rate
produc
neural
network
approach
recent
effort
direct
toward
problem
identifi
aggreg
promiscu
inhibitor
seidler
colleagu
screen
clinic
prescrib
drug
found
seven
show
aggregatebas
inhibit
blactamas
chymotrypsin
malat
dehydrogenas
experiment
result
use
develop
data
set
compound
contain
aggreg
nonaggreg
simpl
cutoff
base
solubl
clogp
classifi
compound
correctli
respect
obtain
precis
model
recurs
partit
algorithm
base
physicochem
descriptor
develop
figur
shown
tabl
model
correctli
classifi
aggreg
nonaggreg
neural
network
svm
method
describ
preced
section
test
compound
aggreg
test
set
result
describ
fulli
briefli
tabl
neural
net
identifi
aggreg
nonaggreg
matthew
correl
coeffici
svm
method
correctli
predict
aggreg
nonaggreg
matthew
correl
coeffici
summari
method
discrimin
aggreg
nonaggreg
well
recurs
partit
model
one
obviou
caus
model
train
data
set
contain
frequent
hitter
act
varieti
mechan
simpli
aggreg
nonetheless
remark
algorithm
perform
well
given
molecul
train
specif
design
aggreg
nonaggreg
inde
intrigu
consid
frequent
hitter
data
set
may
includ
yet
unidentifi
aggreg
therebi
contribut
success
model
recent
addit
compound
test
aggreg
result
increas
number
publicli
report
compound
studi
properti
order
magnitud
databas
compound
explicitli
found
aggreg
nonaggreg
grow
hope
data
provid
greater
insight
natur
aggreg
enabl
develop
precis
model
certain
molecular
scaffold
encod
recognit
divers
receptor
privileg
substructur
often
start
point
design
ligand
improv
specif
particular
receptor
section
review
two
pharmacophorebas
studi
describ
use
privileg
substructur
design
g
proteincoupl
receptor
gpcr
target
compound
librari
identifi
promiscu
kinas
inhibitor
mason
cowork
introduc
method
gener
pharmacophor
could
modifi
includ
pharmacophor
particular
substructur
privileg
scaffold
use
chemx
atom
type
automat
gener
assign
featur
type
use
gener
pharmacophor
atom
type
dummi
centroid
atom
uniqu
privileg
substructur
design
special
privileg
featur
type
featur
type
design
one
four
point
use
gener
pharmacophor
map
compound
subsequ
pharmacophor
descriptor
set
contain
privileg
substructur
molecular
similar
divers
could
compar
rel
share
privileg
scaffold
author
propos
could
use
aid
librari
design
either
imit
featur
known
activ
compound
explor
miss
divers
among
exist
compound
contain
desir
scaffold
latter
goal
could
accomplish
use
molecul
contain
privileg
substructur
reagent
obtain
desir
chemic
access
product
addit
method
shown
identifi
pharmacophor
enrich
among
class
ligand
share
similar
biolog
activ
instanc
structur
featur
share
gpcr
ligand
distinguish
set
small
molecul
enzym
inhibitor
set
random
compound
method
could
also
use
address
ligand
select
compar
pharmacophor
key
across
set
ligand
relat
enzym
trypsin
thrombin
factor
xa
recent
work
explor
use
pharmacophor
describ
relat
bind
site
instanc
see
subsequ
report
aronov
murcko
deriv
fivepoint
pharmacophor
describ
kinas
frequent
hitter
work
frequent
hitter
defin
compound
k
valu
less
nm
two
follow
divers
kinas
protein
kinas
src
select
inhibitor
defin
compound
k
valu
less
nm
one
five
kinas
greater
nm
four
promiscu
select
compound
known
exhibit
atpcompetit
kinas
inhibit
nanomolar
concentr
total
author
compil
set
frequent
hitter
select
inhibitor
ligandbound
structur
four
promiscu
compound
solv
inhous
structur
align
use
gener
fivepoint
pharmacophor
compos
two
hydrogen
bond
donor
two
hydrogen
bond
acceptor
one
aromat
featur
result
compar
frequent
hitter
select
inhibitor
data
set
describ
frequent
hitter
select
inhibitor
match
pharmacophor
consid
select
inhibitor
k
valu
less
nm
one
kinas
greater
specif
compound
match
pharmacophor
therefor
pharmacophor
captur
featur
distinguish
frequent
hitter
specif
inhibitor
place
pharmacophor
featur
atp
bind
site
possibl
identifi
interact
conserv
kinas
residu
frequent
hitter
contribut
inhibitor
promiscu
author
propos
either
addit
featur
beyond
five
associ
promiscu
subtract
least
one
substructur
repres
pharmacophor
might
possibl
engin
ligand
greater
specif
given
kinas
reactiv
speci
chemic
reactiv
group
wellknown
sourc
falseposit
screen
hit
sever
commerci
inhous
filter
identifi
remov
reactiv
speci
current
use
despit
widespread
use
filter
reactiv
compound
remain
signific
challeng
discoveri
effort
exampl
blanchard
cowork
report
ht
hit
coronaviru
proteas
discard
repeat
assay
dtt
suggest
thiol
reactiv
address
persist
problem
hajduk
group
abbott
propos
thiol
reactiv
index
tri
estim
probabl
given
compound
reactiv
recent
develop
alarm
nmr
method
detect
thiol
reactiv
found
lead
compound
experiment
shown
reactiv
predict
comput
filter
better
defin
relev
moieti
structur
descriptor
calcul
seri
reactiv
compound
probabl
reactiv
p
r
given
structur
defin
sum
structur
descriptor
number
occurr
descriptor
compound
weight
tri
descriptor
p
r
compound
greater
compound
predict
reactiv
tri
descriptor
determin
use
nonlinear
regress
maxim
agreement
observ
predict
reactiv
describ
score
function
final
set
nonzero
tri
appli
data
set
compound
studi
alarm
nmr
use
p
r
experiment
reactiv
compound
correctli
predict
experiment
nonreact
compound
correctli
predict
describ
method
high
sensit
low
number
fals
neg
make
use
flag
identifi
compound
followup
experiment
reactiv
test
interfer
assay
readout
anoth
familiar
sourc
screen
fals
posit
comput
approach
remov
activ
due
experiment
artifact
develop
jenkin
colleagu
propos
virtual
screen
use
filter
compound
underli
hypothesi
true
posit
enrich
virtual
screen
fals
posit
due
experiment
artifact
deenrich
explor
idea
nation
cancer
institut
divers
set
chembridg
diverset
combin
produc
librari
compound
initi
dock
angiogenin
fluorescencebas
ht
distinguish
true
hit
fals
posit
ht
hit
rescreen
luciferas
assay
hplc
assay
initi
ht
hit
confirm
true
hit
followup
assay
databas
compound
also
test
angiogenin
two
separ
virtual
screen
one
use
dockvis
dock
ludi
score
second
use
gold
dock
score
comput
method
evalu
abil
enrich
true
hit
among
total
dock
librari
also
among
ht
hit
list
dockvisionludi
combin
rank
true
hit
top
total
databas
enrich
random
gold
algorithm
place
true
hit
top
yield
enrich
ht
hit
dock
highest
enrich
observ
consensu
score
method
count
compound
rank
top
virtual
screen
method
approach
place
four
true
hit
among
top
ht
hit
enrich
ht
alon
author
conclud
virtual
screen
best
use
postht
filter
priorit
compound
test
despit
grow
interest
promiscu
compound
sever
outstand
question
remain
instanc
preval
aggregatebas
inhibitor
particularli
among
small
molecul
interest
drug
design
earli
observ
suggest
compound
may
widespread
among
druglik
compound
work
explor
distribut
aggreg
clearli
need
even
aggreg
found
occupi
substanti
region
relev
chemic
space
signific
behavior
aggreg
featur
bug
sinc
clinic
use
drug
found
capabl
inhibit
enzym
form
aggreg
one
could
make
argument
aggreg
signific
problem
drug
design
inde
recent
studi
propos
aggreg
may
necessari
step
system
uptak
nnrti
suggest
aggreg
may
even
desir
properti
clearli
possibl
drug
show
aggregationbas
inhibit
compound
specif
nanomolar
concentr
pharmacolog
target
may
also
aggreg
micromolar
concentr
inde
interest
specul
possibl
consequ
aggreg
drug
aggreg
micromolar
concentr
lead
inhibit
nontarget
receptor
chang
fact
drug
also
inhibit
target
nanomolar
concentr
import
differ
drug
inhibit
offpathway
target
via
aggreg
hit
inhibit
screen
target
via
aggreg
purpos
screen
find
new
lead
inhibitor
design
screen
hit
activ
inhibit
target
receptor
via
aggreg
like
good
start
point
design
work
abandon
furthermor
even
though
screen
hit
share
patholog
aggreg
real
drug
necessarili
follow
may
also
share
desir
featur
classic
inhibit
target
convers
aggreg
micromolar
concentr
exclud
possibl
compound
may
also
act
specif
inhibitor
given
target
nanomolar
concentr
effort
made
explor
mechan
aggregatemedi
inhibit
experi
rais
question
natur
physicochem
interact
enzym
molecul
aggreg
particl
recent
studi
nanoparticlemedi
inhibit
chymotrypsin
may
provid
insight
function
amphiphil
nanoparticl
found
inhibit
chymoptrypsin
via
electrostat
interact
follow
denatur
enzym
activ
restor
addit
surfact
depend
particular
function
group
expos
surfac
nanoparticl
variou
mode
degre
inhibit
observ
variou
biophys
experi
includ
fluoresc
fluoresc
anisotropi
dl
circular
dichroism
perform
studi
conform
chang
induc
enzym
due
nanoparticl
bind
similar
experi
explor
natur
aggregatemedi
enzym
inhibit
may
worthwhil
also
interest
consid
scope
receptor
target
small
molecul
aggreg
instanc
enzym
suscept
inhibit
aggreg
enzym
due
variat
protein
size
shape
surfac
charg
distribut
physicochem
properti
addit
work
date
done
solubl
enzym
aggreg
also
identifi
screen
use
membranebound
receptor
aggreg
compound
gener
inhibit
surfac
receptor
inhibit
compar
solubl
enzym
aggreg
act
agonist
well
antagonist
question
activ
area
research
result
studi
eagerli
anticip
final
area
interest
concern
sar
among
aggreg
distinguish
aggreg
nonaggreg
factor
determin
size
particl
form
aggreg
preliminari
observ
made
group
instanc
frenkel
colleagu
analyz
sar
among
aggreg
nnrti
found
compound
contain
oxygen
atom
tend
form
larger
particl
author
propos
oxygen
abil
serv
hydrogen
bond
donor
could
result
differ
interact
similarli
place
carbon
nitrogen
atom
consequ
lead
differ
aggreg
pattern
separ
studi
seidler
cowork
studi
seri
azol
antifung
four
aggreg
former
two
interestingli
two
nonaggreg
prescrib
oral
avail
medic
four
aggreg
administ
topic
agent
compound
could
distinguish
base
clogp
valu
aggreg
clogp
greater
nonaggreg
valu
less
addit
physic
properti
potenti
structur
descriptor
suggest
variou
comput
model
describ
addit
pharmacophorebas
method
may
use
approach
studi
sar
among
compound
hope
small
molecul
explicitli
studi
aggreg
structur
influenc
lead
aggreg
better
defin
mechan
better
understood
